In vitro investigation of BK-218, a new oral and parenteral cephalosporin.
AUTOR(ES)
Szabó, I
RESUMO
The antibacterial activity of BK-218 was similar to that of cefamandole when it was tested against several laboratory strains. The inhibiting effect of BK-218 was greater than that of cephalexin and cefoxitin on penicillin-binding proteins of Escherichia coli HB101. This result was in close correlation with the relative inhibition of radiolabeled glucosamine incorporation (greatest with BK-218) and with the lytic effect (most intensive with BK-218). BK-218 proved to be a good inhibitor for all five of the beta-lactamases that were investigated, although two enzymes (Enterobacter cloacae P99 and Pseudomonas aeruginosa Cilote) hydrolyzed it to some extent.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=171585Documentos Relacionados
- In vitro activity of ME1228, a new parenteral cephalosporin.
- In vitro activity of BMY-28100, a new oral cephalosporin.
- In vitro activity of BAY v 3522, a new oral cephalosporin.
- In vitro antibacterial activity of ME1207, a new oral cephalosporin.
- In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
